Trial Profile
Randomized, Blinded, Multicenter, Phase 2 Study Comparing Veliparib Plus FOLFIRI ± Bevacizumab Versus Placebo Plus FOLFIRI ± Bevacizumab in Previously Untreated Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2019
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Sponsors AbbVie; AbbVie Germany
- 03 Apr 2019 Results of ctDNA analysis assessing on-treatment genomic alterations, presented at the 110th Annual Meeting of the American Association for Cancer Research
- 22 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 11 Dec 2018 Results evaluating the efficacy and tolerability of veliparib plus FOLFIRI chemotherapy regimen in previously untreated metastatic colorectal cancer patients published in the British Journal of Cancer